Specialty Pharmacy

FDA approves Gallium 68 PSMA-11, the first drug for PET imaging of prostate-specific membrane antigen–positive lesions in patients with prostate cancer.

Despite the COVID-19 pandemic, several promising drugs are expected to hit the market in late 2020 and early 2021.

Further, the findings suggest that cancer survivors are also likely to be at an increased risk of severe coronavirus disease 2019 (COVID-19) outcomes, given that both influenza and COVID-19 are both epidemic respiratory viruses.

FDA grants fast track designation to irinotecan liposome injection (Onivyde; MM-398) as second-line monotherapy for patients with small cell lung cancer whose disease progressed following a platinum-based chemotherapy regimen.

Investigators hope discovery will lead to new treatments for pancreatic cancer.

Pralsetinib (Gavreto) approved for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer.

Medicaid expansion was associated with a 2% drop in cancer mortality, a recent study found.

In the digital age, exponential technologies are converging and transforming how we engage in health care.

The FDA has granted a breakthrough therapy designation to zanidatamab for the treatment of patients with HER2 gene–amplified biliary tract cancer who have received prior therapy.

FDA grants fast track designation to the BTK inhibitor rilzabrutinib for the treatment of patients with immune thrombocytopenia.

Residency programs in specialty pharmacy are relatively new, emerging in response to dramatic growth in the specialty sector.

Researchers hope clinical trials will begin soon to evaluate oral LMTK3 inhibitors across cancer types.

A review of the biologics license application for lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma following at least 2 previous therapies has been delayed.

PD-L1 IHC 22C3 pharmDx will aid in the identification of patients with triple-negative breast cancer eligible for treatment with pembrolizumab.

Although a single IVIG dose of 25 g was effective in most cases, for some strains repeated doses were necessary to achieve a significant reduction in superantigenic responses.

In the years following the passage of the Affordable Care Act, early-stage cancer diagnosis increased while late-stage fell.

In a trial, 91% of patients rated Sutab as very easy to tolerable to consume, and 78% said they would request Sutab again for a future colonoscopy.

Pharmacists and other medical experts also have a great opportunity to use social media to correct misconceptions, provide guidance, and steer patients toward credible sources.

The FDA approved FoundationOne Liquid CDx as a companion diagnostic with olaparib for certain patients with metastatic castration-resistant prostate cancer.

Pharmacy Times® interviewed Petros Grivas, MD, PhD, associate professor at the University of Washington and Fred Hutchinson Cancer Research Center and a medical oncologist at Seattle Cancer Care Alliance, on the work of the COVID-19 and Cancer Consortium.

A final vote that assessed whether the findings from the EMERGE trial served as primary evidence for the efficacy of aducanumab in Alzheimer disease was 10–0 that the trial did not provide evidence.

A new breast cancer combination treatment may help patients with certain gene mutations, according to a study published in Molecular Cell.

A new device that delivers doses in tenths of a second rather than minutes may bypass adverse effects associated with traditional cancer radiation therapy.

The study found patients who received radiation 34 days or fewer before their infusion with CART-B cell maturation antigen (BCMA) cells did not have worse rates of severe cytokine release syndrome or neurotoxicity, which are 2 common adverse effects of the cellular therapy.

Inappropriately prescribed medications can increase the risk of serious adverse effects and increase the cost of care.

Black women experience longer waiting periods before treatment is initiated than White women following a breast cancer diagnosis, as well as a prolonged treatment duration compared with White women.

The current acute treatments for migraines have shown efficacy and safety, however, approximately one-third of people do not respond, cannot use these options due to contraindications, or report dissatisfaction in therapy.

Angiotensin receptor II blockers are often prescribed to control hypertension or for heart failure, kidney failure, or following a heart attack.